Heart failure remains a substantial burden for patients due to its high prevalence and limited therapeutic options. Heart ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Tectonic Therapeutic, Inc.’s TECX share price has dipped by 14.44%, which has investors questioning if this is right time to buy.

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successf ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to macrophage-based therapies, and clues behind why ...

In an interview with THE WEEK, Professor Chuan He, lead researcher at the University of Chicago, talks about the new findings ...

Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...

Treatment with TNF inhibitors yielded no differences in outcomes vs. other antirheumatic therapies among U.S. veterans with ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...